LOAd-703 is under clinical development by Lokon Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LOAd-703’s likelihood of approval (LoA) and phase transition for Pancreatic Ductal Adenocarcinoma took place on 18 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LOAd-703 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
LOAd-703 is under development for the treatment of pancreatic cancer including pancreatic ductal adenocarcinoma, biliary cancer, colorectal cancer, fallopian tube cancer, epithelial ovarian cancer, primary peritoneal cancer, colorectal carcinoma (CRC), pancreatic carcinoma (PC), biliary cancer, epithelial ovarian carcinoma, malignant melanoma and B-cell lymphoma. It is administered through intratumoral route as a suspension and it is an oncolytic adenovirus consist of serotype 5 from serotype 35 (Ad5/35) which is modified to express CD40 ligand (CD40L) and 4-1BBL. It was also under development for gallbladder cancer.
Lokon Pharma overview
Lokon Pharma, is a developer of immuno-stimulatory gene therapies primarily based on oncolytic adenoviruses. The company is headquartered in Sweden.
Quick View LOAd-703 LOA Data
|Highest Development Stage|